Market Place
Sourcing Support
Trump announces Drug Pricing Deal with Regeneron
27 Apr 2026 //
REUTERS
FDA Approves Regeneron`s Gene Therapy for Hearing Loss
23 Apr 2026 //
BIOSPACE
Dupixent Receives EU Approval For Young Children With CSU
13 Apr 2026 //
PRESS RELEASE
EYLEA HD Approved by FDA with Up to 5-Month Dosing for wAMD/DME
02 Apr 2026 //
GLOBENEWSWIRE
Dupixent Approved in Japan for Bullous Pemphigoid (BP)
24 Mar 2026 //
PRESS RELEASE
Gene Therapies For Hearing Loss Show Promise In Challenging Field
23 Mar 2026 //
BIOSPACE
Regeneron-Licensed Olatorepatide Shows Ph3 Obesity Data China
09 Mar 2026 //
GLOBENEWSWIRE
EU CHMP Recommends Dupixent for Pediatric Chronic Urticaria
27 Feb 2026 //
PRESS RELEASE
Dupixent picks up 9th FDA approval
25 Feb 2026 //
PRESS RELEASE
Zydus Lifesciences launches Anyra, biosimilar of Aflibercept 2 mg
20 Feb 2026 //
EXPRESSPHARMA
Ocular`s Ophthalmologic Version of Inlyta bests Eylea in ph. 3
17 Feb 2026 //
FIERCE PHARMA
Regeneron Showcases Growing Immunology Pipeline at AAAAI
10 Feb 2026 //
GLOBENEWSWIRE
NICE Recommends Dupilumab For Severe CRSwNP In England & Wales
06 Feb 2026 //
PHARMIWEB
EYLEA HD Injection 8 mg Presentations at Angiogenesis 2026
02 Feb 2026 //
GLOBENEWSWIRE
Regeneron Bets Added Cholesterol Benefit Will Help Obesity Drug
30 Jan 2026 //
REUTERS
Rising Stars: Catie Matthews On Navigating The AI Boom
21 Jan 2026 //
FIERCE PHARMA
Dupixent Approved in Japan for Children Aged 6 to 11 Years
23 Dec 2025 //
GLOBENEWSWIRE
Alvotech, Teva Set U.S. Date For AVT06, Biosimilar To Eylea
19 Dec 2025 //
GLOBENEWSWIRE
Regeneron Rebounds Post Regulatory & Manufacturing Challenges
10 Dec 2025 //
BIOSPACE
ASH: Regeneron eyes simpler regimens to grow bispecifics` reach
08 Dec 2025 //
FIERCE PHARMA
Lynozyfic Shows Strong Responses in NDMM Patients
07 Dec 2025 //
GLOBENEWSWIRE
Regeneron Inks $150 M Pact with Gene Writer Tessera
01 Dec 2025 //
PRESS RELEASE
EU Approves Dupixent As First Targeted Drug For Chronic Urticaria
26 Nov 2025 //
PRESS RELEASE
EU Approves Libtayo as First CSCC Immunotherapy after Surgery
19 Nov 2025 //
GLOBENEWSWIRE
Regeneron Highlights Progress at American Society of Hematology
13 Nov 2025 //
GLOBENEWSWIRE
Regeneron Ph2 Factor XI Antibodies Show Antithrombotic Effect
08 Nov 2025 //
GLOBENEWSWIRE
Dupixent Study Meets Endpoints; sBLA Under FDA Priority Review
07 Nov 2025 //
PRESS RELEASE
Dupixent Secures 2025 Prix Galien USA Best Biotech Product Award
31 Oct 2025 //
GLOBENEWSWIRE
Regeneron Pledges $1B+ For Modex Multispecific Antibodies
29 Oct 2025 //
FIERCE BIOTECH
Zag Bio Emerges With $80M Funding For Tregs Diabetes Candidate
28 Oct 2025 //
FIERCE BIOTECH
Regeneron Scraps 2Seventy`s CAR T For Lymphoma In Strategic Move
24 Oct 2025 //
BIOSPACE
Regeneron, Celltrion Shake Hands On Eylea Biosimilar Settlement
22 Oct 2025 //
FIERCE PHARMA
Libtayo Recommended by CHMP for Adjuvant CSCC in EU
17 Oct 2025 //
GLOBENEWSWIRE
DB-OTO Show Dramatic Hearing Improvements In Genetic Hearing Loss
12 Oct 2025 //
GLOBENEWSWIRE
FDA Expands Regeneron`s Libtayo Treatment for Skin Cancer
09 Oct 2025 //
REUTERS
Sanofi`s Dupixent® For Chronic Spontaneous Urticaria Gains
22 Sep 2025 //
GLOBENEWSWIRE
Sanofi, Regeneron`s Dupixent For Chronic Spontaneous Urticaria
22 Sep 2025 //
GLOBENEWSWIRE
Sanofi`s Libtayo Combo Shows 5-Year Survival Gain in NSCLC
16 Sep 2025 //
INDPHARMAPOST
Sandoz to Launch Eylea Biosimilar in Late 2026 After Settlement
09 Sep 2025 //
FIERCE PHARMA
Libtayo Plus Chemo Shows 5-Year Survival in Advanced Lung Cancer
09 Sep 2025 //
GLOBENEWSWIRE
Regeneron Adjusts Presentation Time at Investor Conference
04 Sep 2025 //
GLOBENEWSWIRE
Regeneron Plans 2026 FDA Filing for siRNA Myasthenia Gravis Drug
27 Aug 2025 //
BIOSPACE
FDA Delays 2 Decisions on Eylea HD Due to Manufacturing Issues
21 Aug 2025 //
FIERCE PHARMA
Regeneron Announces Investor Conference Presentations
07 Aug 2025 //
GLOBENEWSWIRE
Onco360® to Partner as Specialty Pharmacy for Lynozyfic
04 Aug 2025 //
GLOBENEWSWIRE
FDA Declines to Approve Regeneron`s Blood Cancer Drug
02 Aug 2025 //
REUTERS
Regeneron Unveils Strong Q2 2025 Financial and Operating Results
01 Aug 2025 //
GLOBENEWSWIRE
US FDA Approves Regeneron`s Blood Cancer Therapy
04 Jul 2025 //
PRESS RELEASE
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
17 Jun 2025 //
BIOSPACE
Dupixent Beats Xolair in Ph4 Nasal Polyp Study at EAACI 2025
15 Jun 2025 //
PRESS RELEASE
Regeneron Says Weight-Loss Drug Helped Preserve Muscle Mass
03 Jun 2025 //
REUTERS
Regeneron Expands Clinical-Stage Obesity Portfolio
02 Jun 2025 //
PRESS RELEASE
Libtayo Phase 3 Data in Adjuvant Treatment of High-Risk Carcinoma
31 May 2025 //
GLOBENEWSWIRE
Linvoseltamab Combos Show Early Results In R/R Myeloma
22 May 2025 //
GLOBENEWSWIRE
AI Genomics Breakthrough Aligns with Regeneron’s 23andMe Buyout
22 May 2025 //
GLOBENEWSWIRE
Regeneron to Acquire 23andMe in Court-Supervised Sale
19 May 2025 //
GLOBENEWSWIRE
Regeneron plans to buy 23andMe for $256M
19 May 2025 //
ENDPTS
Amgen owes Regeneron $407M after defeat in PCSK9 antitrust suit
17 May 2025 //
FIERCE PHARMA
Dupixent® Data at ATS Show Benefits in Type 2 Lung Inflammation
01 May 2025 //
GLOBENEWSWIRE
After FDA rejection, Regeneron scores EU nod for Lynozyfic
29 Apr 2025 //
FIERCE PHARMA
